Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.


Journal

Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805

Informations de publication

Date de publication:
09 2019
Historique:
received: 24 03 2019
revised: 11 06 2019
accepted: 26 06 2019
entrez: 27 8 2019
pubmed: 27 8 2019
medline: 14 7 2020
Statut: ppublish

Résumé

The aim of the study was to characterize and evaluate the presence of DLL3-positive Circulating Tumor Cells (CTCs) in SCLC patients receiving front-line chemotherapy and assess their clinical relevance. Peripheral blood was obtained from treatment-naïve patients with SCLC (n = 108 patients), after one etoposide/platinum cycle (n = 68 patients) and on disease progression (n = 48 patients). Immunofluorescence staining using antibodies against the DLL3, cytokeratins (CK), CD45 and vimentin (Vim) was used for the detection and characterization of CTCs. Before treatment, 74.1% of patients had detectable DLL3 These findings demonstrate an important heterogeneity of CTCs, based on the expression of CK, Vim and DLL3, in patients with SCLC and the changes of DLL3

Identifiants

pubmed: 31447000
pii: S0169-5002(19)30518-5
doi: 10.1016/j.lungcan.2019.06.025
pii:
doi:

Substances chimiques

Biomarkers 0
Biomarkers, Tumor 0
DLL3 protein, human 0
Intracellular Signaling Peptides and Proteins 0
Membrane Proteins 0
Vimentin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

33-39

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Ippokratis Messaritakis (I)

Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Greece.

Michalis Nikolaou (M)

Department of Internal Medicine, Medical Oncology Unit, "Marika Iliadi" Hospital of Athens, Greece.

Fillipos Koinis (F)

Department of Medical Oncology, University General Hospital of Larissa, Thessaly, Greece.

Eleni Politaki (E)

Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Greece.

Anastasios Koutsopoulos (A)

Department of Pathology, University General Hospital of Heraklion, Greece.

Eleni Lagoudaki (E)

Department of Pathology, University General Hospital of Heraklion, Greece.

Eleni-Kyriaki Vetsika (EK)

Department of Medical Oncology, University General Hospital of Larissa, Thessaly, Greece.

Vassilis Georgoulias (V)

Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Greece; First Department of Medical Oncology, IASO General Hospital of Athens, Greece.

Athanasios Kotsakis (A)

Department of Medical Oncology, University General Hospital of Larissa, Thessaly, Greece. Electronic address: kotsakis@uoc.gr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH